Japan-based Eisai has obtained approval for review from US Food and Drug Administration (FDA) for its antiepileptic drug Fycompa (perampanel).

The FDA accepted Eisai’s supplemental new drug application (sNDA) for Fycompa, which is being developed to treat primary generalised tonic-clonic seizures (PGTC), a severe form of seizures in patients over the age of 12.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Fycompa is a non-competitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors.

The sNDA application was based on a multicentre, randomised, double-blind, placebo-controlled and parallel-group trial, Study 332.

"Fycompa is designed to treat primary generalised tonic-clonic seizures (PGTC), a severe form of seizures in patients over the age of 12."

The trial was designed to evaluate the efficacy and safety of adjunctive Fycompa therapy in 164 patients over the age of 12 with uncontrolled PGTC seizures, receiving up to a maximum of three antiepileptic drugs.

See Also:

According to the company, the study demonstrated that Fycompa significantly reduced PGTC seizure frequency, and improved responder rates, when compared to a placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Fycompa received approval in more than 40 countries, primarily in Europe and North America, to treat partial-onset seizures in patients with epilepsy over the age of 12.

Eisai said the drug was introduced in the US in January.

The company also submitted an application for European approval for additional indication of the drug, to market in the EU region.